Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. (ENTA) Revenue
Annual & quarterly revenue history · segment & region breakdown
ENTA · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsEnanta Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.07B, a decrease of 3.42% year-over-year from $0.07B in FY2025.
Revenue trend
2025 – 2010 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-09-30 | $0.07B | -$0.00B | -3.42% |
| 2024-09-30 | $0.07B | -$0.01B | -14.61% |
| 2023-09-30 | $0.08B | -$0.01B | -8.07% |
| 2022-09-30 | $0.09B | -$0.01B | -11.24% |
| 2021-09-30 | $0.10B | -$0.03B | -20.74% |
| 2020-09-30 | $0.12B | -$0.08B | -40.31% |
| 2019-09-30 | $0.21B | -$0.00B | -0.69% |
| 2018-09-30 | $0.21B | +$0.10B | +100.97% |
| 2017-09-30 | $0.10B | +$0.01B | +16.48% |
| 2016-09-30 | $0.09B | -$0.07B | -45.13% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Enanta Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Enanta Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Enanta Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ENTA revenue · 4 questionsENTA's trailing twelve-month (TTM) revenue is $0.07B. That is a decrease of 3.42% year-over-year from $0.07B in FY2025.
▸ Source: FMP · Enanta Pharmaceuticals, Inc. SEC filings · GAAP · Enanta Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026